ES2570632T3 - Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal - Google Patents

Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal

Info

Publication number
ES2570632T3
ES2570632T3 ES08827846T ES08827846T ES2570632T3 ES 2570632 T3 ES2570632 T3 ES 2570632T3 ES 08827846 T ES08827846 T ES 08827846T ES 08827846 T ES08827846 T ES 08827846T ES 2570632 T3 ES2570632 T3 ES 2570632T3
Authority
ES
Spain
Prior art keywords
colorectal cancer
elastase inhibitor
leukocyte elastase
determination procedure
inhibitor determination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08827846T
Other languages
English (en)
Inventor
Corinne Beaulieu
Jean-Philippe Charrier
Geneviève Choquet-Kastylevsky
Odile Mejan-Letourneur
Dominique Rolland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA filed Critical Biomerieux SA
Application granted granted Critical
Publication of ES2570632T3 publication Critical patent/ES2570632T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procedimiento de diagnóstico in vitro del cáncer colorrectal por determinación del aumento de la concentración, con respecto a los valores determinados para los sujetos sanos, del marcador Inhibidor de la elastasa de los leucocitos en una muestra biológica procedente de un paciente sospechoso de padecer cáncer colorrectal.
ES08827846T 2007-07-19 2008-07-10 Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal Active ES2570632T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0705202A FR2919063B1 (fr) 2007-07-19 2007-07-19 Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
PCT/FR2008/051291 WO2009024691A2 (fr) 2007-07-19 2008-07-10 Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal

Publications (1)

Publication Number Publication Date
ES2570632T3 true ES2570632T3 (es) 2016-05-19

Family

ID=38921769

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08827846T Active ES2570632T3 (es) 2007-07-19 2008-07-10 Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal

Country Status (9)

Country Link
US (1) US9891223B2 (es)
EP (1) EP2171469B1 (es)
JP (1) JP5572548B2 (es)
CN (2) CN101855555A (es)
AU (1) AU2008290466B2 (es)
CA (1) CA2693655A1 (es)
ES (1) ES2570632T3 (es)
FR (1) FR2919063B1 (es)
WO (1) WO2009024691A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101680898A (zh) * 2007-05-10 2010-03-24 霍夫曼-拉罗奇有限公司 Timp-1作为结肠直肠癌标志的用途
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
ES2541178T3 (es) 2009-02-03 2015-07-16 Mdxhealth Sa Método de detección de cáncer colorrectal
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
FR2944019B1 (fr) * 2009-04-03 2011-04-22 Biomerieux Sa Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal.
US8808990B2 (en) 2011-05-12 2014-08-19 Exact Sciences Corporation Serial isolation of multiple DNA targets from stool
US8993341B2 (en) 2011-05-12 2015-03-31 Exact Sciences Corporation Removal of PCR inhibitors
CN104450680A (zh) * 2011-05-12 2015-03-25 精密科学公司 核酸的分离
WO2013064163A1 (en) * 2011-11-01 2013-05-10 Academisch Medisch Centrum Methylation markers for colorectal cancer
FR3001805B1 (fr) 2013-02-01 2015-02-20 Biomerieux Sa Procede de detection d'un cancer colorectal
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
CA2923140C (en) * 2013-09-05 2023-09-26 Idexx Laboratories, Inc. Methods for detecting renal disease
US9810702B2 (en) 2014-09-19 2017-11-07 The Cleveland Heartlab, Inc. HDL-associated protein extraction and detection
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
EP3259593B1 (en) 2015-02-20 2022-10-05 IDEXX Laboratories, Inc. Homogenous immunoassay with compensation for background signal
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
CN114574585A (zh) 2015-08-31 2022-06-03 梅约医药教育及研究基金会 检测胃肿瘤
CN106596977B (zh) * 2017-02-08 2018-06-08 南京医科大学第一附属医院 ezrin在制备哮喘诊断试剂中的应用
MX2020003523A (es) 2017-10-19 2020-07-22 Idexx Lab Inc Deteccion de dimetilarginina simetrica.
CN109613254B (zh) * 2018-11-06 2022-04-05 上海市公共卫生临床中心 一种用于肿瘤治疗和诊断的靶点标志物pdia2
US10900091B2 (en) * 2019-03-15 2021-01-26 The Chinese University Of Hong Kong miR-133a as a marker for colorectal cancer
CN110426471B (zh) * 2019-08-02 2022-02-18 山东省食品药品检验研究院 一种婴幼儿食品中生物素含量的测定方法
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529931A (en) * 1983-04-07 1985-07-16 Ford Motor Company Single-coil current measuring circuit
FR2581456B1 (fr) 1985-05-02 1987-07-17 Pasteur Institut Villine humaine, en tant que marqueur de cellules malignes primaires originaires du tube digestif, et moyens, en particulier anticorps diriges contre la villine humaine, pour la detection desdites cellules malignes
US5002870A (en) * 1988-06-07 1991-03-26 California Institute For Medical Research Plastin isoforms and their use
US5360715A (en) * 1988-06-07 1994-11-01 California Institute Of Technology Plastin isoforms and their uses
JP2816175B2 (ja) 1989-04-28 1998-10-27 三菱電機株式会社 直流電流測定装置
US5223789A (en) * 1989-06-23 1993-06-29 Fuji Electric Co., Ltd. AC/DC current detecting method
JPH0464068A (ja) 1990-07-02 1992-02-28 Fuji Electric Co Ltd 直流電流検出方法
CA2054149A1 (en) 1990-10-29 1992-04-30 Eric Pringault Villin gene promoter sequence and its use in vectors, transformed mammalian cell lines, transgenic animals, and cell lines derived from the animals
US5344760A (en) * 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
US6291205B1 (en) 1992-06-12 2001-09-18 Merck & Co., Inc. Method of increasing production of disulfide bonded recombinant proteins by saccharomyces cerevisiae
JPH08149981A (ja) 1993-12-13 1996-06-11 La Jolla Inst For Allergy & Immunology Ｔ細胞α鎖による抗原特異的免疫制御の方法
US6001632A (en) * 1996-05-15 1999-12-14 Incyte Pharmaceuticals, Inc. Human protein disulfide isomerase
US6518411B1 (en) 1996-11-22 2003-02-11 University Of Iowa RGS compositions and therapeutic and diagnostic uses therefor
DE69934139D1 (de) 1998-12-01 2007-01-04 Wrair Walter Reed Army Inst Of Diagnose von krebsstadium oder aggressivität
JP2002536995A (ja) 1999-02-22 2002-11-05 インサイト・ファーマスーティカルズ・インコーポレイテッド 結腸の疾患に関連する遺伝子
US6451528B1 (en) 1999-03-16 2002-09-17 Oregon Health & Sciences University Sperm-specific AKAP protein genes and uses
NZ515311A (en) * 1999-04-09 2002-11-26 Rigshospitalet Mass screening and highly specific early identification of colorectal or metastatic breast cancer by measuring TIMP-1 tissue inhibitor
JP4019208B2 (ja) 1999-09-01 2007-12-12 有機合成薬品工業株式会社 新規酵素及びその製造方法
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
JP2004508801A (ja) 1999-10-29 2004-03-25 カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ ナイセリア抗原性ペプチド
WO2001071357A2 (en) 2000-03-20 2001-09-27 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of breast cancer
AU2001289864A1 (en) 2000-09-08 2002-03-22 Bayer Aktiengesellschaft Regulation of human protein disulfide isomerase-like enzyme
AU2001294943A1 (en) * 2000-10-02 2002-04-15 Bayer Corporation Nucleic acid sequences differentially expressed in cancer tissue
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
WO2002036624A2 (en) * 2000-10-30 2002-05-10 Board Of Regents, The University Of Texas System Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof
US20030082533A1 (en) * 2001-01-26 2003-05-01 Henry Yue Intelectin
AU2002251844A1 (en) * 2001-02-02 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
DE10118774A1 (de) 2001-04-17 2002-10-31 Jerini Ag Verfahren zur Bestimmung der Substratspezifität einer enzymatischen Aktivität und Vorrichtung hierzu
US20040018973A1 (en) 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
GB0208331D0 (en) 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
CN1396182A (zh) 2002-07-31 2003-02-12 陕西超英生物医学研究开发有限公司 人内皮生长因子受体2蛋白全人单克隆抗体及其制备方法
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
KR100595364B1 (ko) 2003-02-20 2006-07-03 재단법인 목암생명공학연구소 Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
ATE412182T1 (de) * 2003-07-21 2008-11-15 Hoffmann La Roche Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
WO2005015218A1 (en) * 2003-07-21 2005-02-17 Roche Diagnostics Gmbh Use of proteins proteinase 3 (prn3) and leukocyte elastase inhibitor (ileu) as a marker for colorectal cancer
WO2005015226A1 (en) 2003-08-08 2005-02-17 Roche Diagnostics Gmbh Use of protein t-plastin (plst) as a marker for colorectal cancer
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
EP1692519B1 (en) * 2003-12-03 2010-06-02 Glycominds Ltd. Method for diagnosing diseases based on levels of anti-glycan antibodies
WO2005060996A2 (en) 2003-12-23 2005-07-07 Lauras As Method of altering the pka type i signalling pathway
US20050181398A1 (en) * 2004-01-16 2005-08-18 Fung Eric T. Specific detection of host response protein clusters
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
CA2569079A1 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
WO2006015079A2 (en) * 2004-07-27 2006-02-09 Yale University Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
AT500719B1 (de) 2004-09-08 2010-06-15 Red Bull Gmbh Chaperone als tumormarker
CN101065393A (zh) * 2004-09-30 2007-10-31 优基谱 用于结肠直肠癌早期检测的药物筛选和分子诊断检测：试剂、方法及其试剂盒
WO2006053439A1 (en) 2004-11-18 2006-05-26 Valorisation Hsj, Societe En Commandite Hcv f protein and uses thereof
CA2593184A1 (en) 2005-01-06 2006-07-13 Eastern Virginia Medical School Apolipoprotein a-ii isoform as a biomarker for prostate cancer
US20060192550A1 (en) 2005-02-25 2006-08-31 Sandquist David A Current sensor with magnetic toroid single frequency detection scheme
EP1724586A3 (en) 2005-05-21 2007-07-04 ProteoSys AG Annexin for cancer risk assessment
WO2007002535A2 (en) 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
WO2007020522A2 (en) * 2005-08-18 2007-02-22 Zadec Aps Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
EP1775590A1 (en) 2005-10-11 2007-04-18 Laboratorios S.A.L.V.A.T., S.A. Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
US9095549B2 (en) * 2005-12-16 2015-08-04 Electrophoretics Limited Diagnosis and prognosis of colorectal cancer
WO2007140352A2 (en) 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008028968A2 (en) 2006-09-08 2008-03-13 Institut Gustave Roussy Compounds regulating calreticulin, kdel receptor and/or erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
EP2083857A4 (en) 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal

Also Published As

Publication number Publication date
US9891223B2 (en) 2018-02-13
FR2919063A1 (fr) 2009-01-23
WO2009024691A2 (fr) 2009-02-26
EP2171469B1 (fr) 2016-02-17
CN105954515B (zh) 2019-02-22
CA2693655A1 (fr) 2009-02-26
AU2008290466B2 (en) 2014-04-03
CN105954515A (zh) 2016-09-21
US20100129828A1 (en) 2010-05-27
CN101855555A (zh) 2010-10-06
FR2919063B1 (fr) 2009-10-02
JP5572548B2 (ja) 2014-08-13
JP2010533851A (ja) 2010-10-28
WO2009024691A3 (fr) 2009-05-22
AU2008290466A1 (en) 2009-02-26
EP2171469A2 (fr) 2010-04-07

Similar Documents

Publication Publication Date Title
ES2570632T3 (es) Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
MX366653B (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
ES2570627T3 (es) Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal
BRPI0906858B8 (pt) métodos in vitro para detectar a presença de uma célula de câncer em um indivíduo e para identificar uma assinatura específica de tumor em um indivíduo tendo câncer.
MX382244B (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
CL2007001571A1 (es) Perfil genico indicativo de probabilidad aumentada de que un paciente responda o no a una inmunoterapia; uso de dicho perfil; procedimiento de identificacion del perfil; uso de sonda para identificar la expresion diferencial de al menos un gen de act
WO2011015602A3 (en) Lung cancer biomarkers
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
MX2010014228A (es) Metodos y productos de diagnostico del p/gf-1 acompañante.
MX2007004342A (es) Moleculas cop1 y uso de las mismas.
ES2674177T3 (es) Preparación de suero
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2009009841A (es) Metodos para determinar la respuesta de la leucemia mieloide aguda al tratamiento con farnesiltransferasa.
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
MX2022014741A (es) Metodos para detectar bordetella.
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal